No CrossRef data available.
Article contents
P0058 - Mirtazapine in the treatment of anxiety associated with depression
Published online by Cambridge University Press: 16 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:
Most patients with depression have symtoms of anxiety. Aim of our study was to investigate the efficacy of Mirtazapine on symptoms of anxiety in patients with depression. Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA).Sedation may be a useful side-effect in the treatment of depressed patients with insomnia and severe anxiety.
Methods:
Total of 40 patients, with diagnosis F 32.0-F 32.2 or F 33.0-F 33.2 (according to ICD-10), with a high degree of anxiety, were enrolled. Anxiety was assessed using the Inner Tension item (item 3) of the Montgomery-Asberg Depression Rating Scale (MADRS). Patients received Mirtazapine 30mg/day 6 weeks, without concomitant medication. The visits were organized at the beginning of treatment, after 2,4 and 6 weeks of treatment.Gathered data were statistically processed.
Results:
There was a significant improvement for Mirtazapine-treated patients in the Item 3 of the MADRS at weeks 2,4 and 6 versus baseline.
Conclusion:
Mirtazapine showed a significant beneficial effect in reducing symptoms of anxiety in depressive patients with high degree of anxiety, with early onset of action.
- Type
- Poster Session II: Antidepressants
- Information
- European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S209
- Copyright
- Copyright © European Psychiatric Association 2008
You have
Access
Comments
No Comments have been published for this article.